Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

 

NewsBIOLAN HEALTH has developed a rapid serological test for the detection of antibodies against SARS-CoV-2, the virus that causes COVID-19.

https://biolanhealth.com/wp-content/uploads/2021/02/eitb_opt-450.jpg
December 14, 2020by BIOLAN HEALTH

A new serological test to detect IgG and IgM antibodies against SARS-CoV-2 has been developed by BIOLAN HEALTH. It is a rapid and easy to use test that, from a drop of capillary blood, will identify people who are or have been infected by the virus that causes COVID-19.

A very distinctive feature of the BIOLAN HEALTH test is that it can detect antibodies directed against the area of SARS-CoV-2 responsible for the entry of the virus into the cell, the Receptor Binding Domain (RBD) of the Spike-1 protein. These RBD-targeting antibodies have the potential to be neutralising against SARS-CoV-2 and may therefore prevent future infections. BIOLAN HEALTH’s new serological test will therefore identify people who have neutralising antibodies to SARS-CoV-2 and who are therefore “potentially” immune.

This means that, in addition to being a useful tool for epidemiological studies to better understand the incidence and spread of the virus, it can also be a very useful tool for evaluating the effectiveness of vaccines.

BIOLAN HEALTH itself will be in charge of its manufacture, for which it has set up a specific production line that will soon be complete with all the necessary equipment, as shown in the following report:
https://www.eitb.eus/es/noticias/sociedad/videos/detalle/7680723/video-la-empresa-biolan-zamudio-desarrolla-test-serologico-rapido/